Karas Eric 4
4 · ARS Pharmaceuticals, Inc. · Filed Sep 19, 2024
Insider Transaction Report
Form 4
Karas Eric
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-09-18$1.50/sh+10,000$15,000→ 15,693 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-18−10,000→ 594,588 totalExercise: $1.50Exp: 2032-05-23→ Common Stock (10,000 underlying) - Sale
Common Stock
2024-09-18$14.00/sh−10,000$140,000→ 5,693 total
Footnotes (2)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024.
- [F2]Immediately exercisable.